Journal
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 183, Issue -, Pages 14-21Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2023.08.002
Keywords
Puripotent stem cells; Cardiomyocytes; Cardiovascular progenitor cells; Extracellular vesicles; Exosomes; Chronic heart failure
Categories
Ask authors/readers for more resources
Despite advancements in heart failure management, some patients are not eligible for aggressive treatments. Cell therapy, particularly using pluripotent stem cells, holds promise for improving outcomes. However, clinical trials have yet to conclusively prove the effectiveness of cell-based approaches.
Despite the dramatic improvements in the management of patients with chronic heart failure which have occurred over the last decades, some of them still exhaust conventional drug-based therapies without being eligible for more aggressive options like heart transplantation or implantation of a left ventricular assist device. Cell therapy has thus emerged as a possible means of filling this niche. Multiple cell types have now been tested both in the laboratory but also in the clinics and it is fair to acknowledge that none of the clinical trials have yet conclusively proven the efficacy of cell-based approaches. These clinical studies, however, have entailed the use of cells from various sources but of non-cardiac lineage origins. Although this might not be the main reason for their failures, the discovery of pluripotent stem cells capable of generating cardiomyocytes now raises the hope that such cardiac-committed cells could be therapeutically more effective. In this review, we will first describe where we currently are with regard to the clinical trials using PSC-differentiated cells and discuss the main issues which remain to be addressed. In parallel, because the capacity of cells to stably engraft in the recipient heart has increasingly been questioned, it has been hypothesized that a major mechanism of action could be the cell triggered release of biomolecules that foster host-associated reparative pathways. Thus, in the second part of this review, we will discuss the rationale, clinically relevant advantages and pitfalls associated with the use of these PSC products.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available